May 8, 2008
More...
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylam's common ... via BioSpace
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

